TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28637357

Group type: EXPERIMENTAL
Intervention: Behavioral intention to take up any type of HIV testing
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Perceived benefit of HIV testing
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Perceived psychological barriers of HIV testing
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Perceived self-efficacy in taking up HIV testing
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Perceived cue to action from non-governmental organization staff
Number of subjects: 141
Study: 27126252

Group type: EXPERIMENTAL
Intervention: Drill instrument
Number of subjects: 10

Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 10
Study: 25149141

Group type: EXPERIMENTAL
Intervention: Growth mindset induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed mindset induction
Number of subjects: 0
Study: 23250532

Group type: EXPERIMENTAL
Intervention: Local immunomodulator (0.04% synthetic tetradecapeptide solution)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional therapeutic modalities
Number of subjects: 75
Study: 20462428

Group type: EXPERIMENTAL
Intervention: 42 g raw walnuts/d for 6 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 21 g raw walnuts/d for 6 weeks
Number of subjects: 21
Study: 18765001

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel (90 mg, once daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal micronized progesterone tablets (200 mg, three times daily)
Number of subjects: 200
Study: 15983221

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/day
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 12503779

Group type: EXPERIMENTAL
Intervention: Intelligent stretching device
Number of subjects: 0
Study: 11019474

Group type: EXPERIMENTAL
Intervention: Outpatient treatment (day care)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Inpatient treatment (hospital admission)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Overall acceptability of outpatient treatment
Number of subjects: 121
Study: 7492487

Group type: EXPERIMENTAL
Intervention: Cyclosporine G
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 0
Study: 2334155

Group type: COMPARATOR
Intervention: 400 mg of norfloxacin alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg of norfloxacin 5 min after aluminum‐magnesium hydroxide (Maalox)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maalox 2 h after 400 mg of norfloxacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg of norfloxacin 5 min after calcium carbonate (Titralac)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antacid administration
Number of subjects: 12
Study: 348210

Group type: EXPERIMENTAL
Intervention: Racemic epinephrine with intermittent positive pressure
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study: 31101323

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 84633

Group type: EXPERIMENTAL
Intervention: Beta blockers (after excluding patients with prior myocardial infarction or heart failure)
Number of subjects: 84633

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 84633

Group type: COMPARATOR
Intervention: Thiazides
Number of subjects: 84633
Study: 28588686

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT) for 24 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 38
Study: 25602877

Group type: EXPERIMENTAL
Intervention: Youth-parent intervention emphasizing adolescent-parent communication
Number of subjects: 2564

Group type: EXPERIMENTAL
Intervention: Parent-only goal-setting intervention
Number of subjects: 2564

Group type: COMPARATOR
Intervention: No parent intervention
Number of subjects: 2564
Study: 23995030

Group type: EXPERIMENTAL
Intervention: Panic management (PM)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (paroxetine)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral therapy (CBT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 69
Study: 20500133

Group type: EXPERIMENTAL
Intervention: Education booklet on bra fit and breast support from a sports physiotherapist
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 115
Study: 18162932

Group type: EXPERIMENTAL
Intervention: Tenofovir (arm B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Stavudine (arm A)
Number of subjects: 18
Study: 16608616

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 130
Study: 12880730

Group type: EXPERIMENTAL
Intervention: Banana leaf dressing (BLD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vaseline gauze (VG)
Number of subjects: 30
Study: 11052924

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (RP) 400000 i.u. administered intramuscularly to 6 patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (28 patients not given RP)
Number of subjects: 34
Study: 1341892

Group type: EXPERIMENTAL
Intervention: OK-432 (1KE or 5KE) administered one or 3 times every other day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: OK-432 (repeated injections)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: OK-432 (doses more than 5 KE)
Number of subjects: 39
Study: 6230953

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 72
Study: 31518224

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30084892

Group type: EXPERIMENTAL
Intervention: Weekly short-term lotteries for 13 weeks
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Short-term lotteries combined with an additional long-term lottery after 26 weeks
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control arm without lotteries
Number of subjects: 163
Study: 26995281

Group type: EXPERIMENTAL
Intervention: 12-month digital health weight loss intervention including algorithm-generated tailored behavior change goals, self-monitoring via mobile technologies, daily self-weighing using a network-connected scale, skills training materials, 18 counseling phone calls with a Track coach, and primary care provider counseling.
Number of subjects: 351

Group type: COMPARATOR
Intervention: Usual primary care (control group)
Number of subjects: 351
Study: 24651209

Group type: EXPERIMENTAL
Intervention: VIB + PT (physiotherapy plus vibration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SHAM + PT (physiotherapy and sham vibration)
Number of subjects: 30
Study: 22018075

Group type: EXPERIMENTAL
Intervention: Low-intensity training model (1 year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity training model (nearly 3 years)
Number of subjects: 0
Study: 20197161

Group type: EXPERIMENTAL
Intervention: Traditional hyrax tooth‐borne expander
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bone‐anchored expander
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 16899376

Group type: EXPERIMENTAL
Intervention: Red ring-like cue presented immediately after subjective disappearance of the target in MIB, radius systematically modulated.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flickering cue at 1Hz with a critically small radius.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrupt onset of a small square cue.
Number of subjects: 0
Study: 16087696

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus gemcitabine (PG)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Gemcitabine (G)
Number of subjects: 565
Study: 12126240

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Omeprazole (20 mg)
Number of subjects: 300
Study: 10639654

Group type: EXPERIMENTAL
Intervention: Physiotherapy (dynamic protocol under supervision, 9 sessions of 30 min each over 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment (verbal and written advice and exercises)
Number of subjects: 20
Study: 11540403

Group type: EXPERIMENTAL
Intervention: 5 mg/70 kg d-methamphetamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg d-methamphetamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1858618

Group type: COMPARATOR
Intervention: Conventional therapy (group I)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP) for 25 +/- 8 hours (group II)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP) (group II)
Number of subjects: 114
Study: 31461183

Group type: EXPERIMENTAL
Intervention: Open flap and grafting (flap-graft)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Open flap and no grafting (flap-nograft)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Flapless and no grafting (noflap-nograft)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study: 28292304

Group type: EXPERIMENTAL
Intervention: iCPR tool with academic detailing about strep pharyngitis and pneumonia diagnosis and treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group with academic detailing about strep pharyngitis and pneumonia diagnosis and treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: iCPR tool
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 27004425

Group type: EXPERIMENTAL
Intervention: GS-9190 single dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GS-9190 multiple doses (8 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GS-9190 multiple doses (4-6 months follow-up)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chimeric HCV replicons with Y448H and Y448H + Y452H/Y
Number of subjects: 36
Study: 25148846

Group type: EXPERIMENTAL
Intervention: Hand and Arm Together (HAT) training (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hand and Arm Separate (HAS) training (n=21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (HAT and HAS)
Number of subjects: 40
Study: 22735873

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 56
Study: 20190467

Group type: EXPERIMENTAL
Intervention: Risedronate monotherapy (n=8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined risedronate and vitamin K(2) therapy (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous steroid pulse therapy (n=6, group C)
Number of subjects: 16
Study: 18187011

Group type: EXPERIMENTAL
Intervention: Psychoeducational lessons on cancer-related topics (10 sessions)
Number of subjects: 294
Study: 15681523

Group type: EXPERIMENTAL
Intervention: Capecitabine (2,500 mg/m2/d)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Capecitabine plus Bevacizumab (15 mg/kg)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Capecitabine plus Bevacizumab
Number of subjects: 462
Study: 11948045

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional oxygen supplementation by Venturi mask
Number of subjects: 26
Study: 11877184

Group type: EXPERIMENTAL
Intervention: UBM dark room provocative test
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional dark room provocative test
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (normal persons)
Number of subjects: 52
Study: 7622821

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 1663853

Group type: EXPERIMENTAL
Intervention: EPO to achieve a hemoglobin of 95-110 g/L
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: EPO to achieve a hemoglobin of 115-130 g/L
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: EPO therapy (both dosages)
Number of subjects: 118
Study: 6972693

Group type: EXPERIMENTAL
Intervention: Prescribed supervised exercise program (intensive exercise in laboratory for 8 weeks, followed by gymnasium exercise for 34 months)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Prescribed supervised exercise program
Number of subjects: 651

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 651
Study: 31694684

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine with paravertebral saline
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Paravertebral lidocaine with intravenous saline
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil with paravertebral saline
Number of subjects: 153

Group type: COMPARATOR
Intervention: Intravenous lidocaine
Number of subjects: 153
Study: 28213775

Group type: EXPERIMENTAL
Intervention: Bipolar diathermy scissors
Number of subjects: 60

Group type: COMPARATOR
Intervention: Harmonic scalpel
Number of subjects: 60
Study: 26482768

Group type: EXPERIMENTAL
Intervention: Salvage Cryotherapy (SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Androgen Deprivation Therapy (ADT)
Number of subjects: 0
Study: 23420911

Group type: EXPERIMENTAL
Intervention: Media diet intervention (substituting high quality prosocial and educational programming for aggression-laden programming)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Media diet intervention
Number of subjects: 565
Study: 21178814

Group type: EXPERIMENTAL
Intervention: Near-infrared light device (device group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Traditional methods (standard group)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Device (qualitative assessment by nurses)
Number of subjects: 123
Study: 19833260

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg, followed by 80 mg
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg, followed by 80 mg
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg, followed by 40 mg
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: SLCO1B1*5 genotype
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Gene-dose effect
Number of subjects: 509
Study: 17537739

Group type: EXPERIMENTAL
Intervention: Liaison psychiatric nursing
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual treatment by hospital and primary care staff
Number of subjects: 121
Study: 15350880

Group type: EXPERIMENTAL
Intervention: In-person verbal interactions
Number of subjects: 29

Group type: COMPARATOR
Intervention: Remote verbal interactions
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Verbal interactions (both conditions)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Faster-paced verbal task (Experiment 2)
Number of subjects: 29
Study: 11519773

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (MP) 200 mg
Number of subjects: 182

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 5 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both MP and MPA
Number of subjects: 182
Study: 9801119

Group type: EXPERIMENTAL
Intervention: Desmopressin (20 microg/day)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study: 8010466

Group type: EXPERIMENTAL
Intervention: Early epidural analgesia (bupivacaine)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Late administration of epidural analgesia (after 5 cm dilation) with prior intravenous nalbuphine (10 mg)
Number of subjects: 334
Study: 2686320

Group type: EXPERIMENTAL
Intervention: Sinestrol 1 mg orally twice a day for 3 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (14 patients with PMDD aged 7 to 9 years)
Number of subjects: 15
Study: 843185

Group type: EXPERIMENTAL
Intervention: Short-term hospitalization
Number of subjects: 74

Group type: COMPARATOR
Intervention: Long-term hospitalization
Number of subjects: 74
Study: 31774584

Group type: EXPERIMENTAL
Intervention: Lorcaserin (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28855417

Group type: EXPERIMENTAL
Intervention: Methionine intake (0, 5, 10, 15, 25, and 35 mg · kg‐1 · d‐1) with no Cys in the diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methionine intake (0, 2.5, 5, 7.5, 10, and 15 mg · kg‐1 · d‐1) with 21 mg · kg‐1 · d‐1 Cys
Number of subjects: 5

Group type: COMPARATOR
Intervention: Healthy children (comparison group)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Comparison of minimum Met requirements between healthy children and children with CRI
Number of subjects: 5
Study: 26860015

Group type: EXPERIMENTAL
Intervention: Bupivacaine (1 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine (0.2 mg/kg)
Number of subjects: 30
Study: 22802269

Group type: EXPERIMENTAL
Intervention: Multimedia training
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Unimodal training
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cold Start condition
Number of subjects: 71
Study: 22063375

Group type: EXPERIMENTAL
Intervention: S50-R50 bupivacaine-loaded microsphere (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% enantiomeric excess bupivacaine-loaded microsphere (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% enantiomeric excess bupivacaine (Group D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microspheres without local anesthetic (Group A)
Number of subjects: 0
Study: 19505304

Group type: EXPERIMENTAL
Intervention: ASAQ orally once daily (ASAQ1)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: ASAQ twice daily (ASAQ2)
Number of subjects: 941

Group type: COMPARATOR
Intervention: Artemether + lumefantrine (AL) twice daily
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: ASAQ1 and ASAQ2
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 941
Study: 19681252

Group type: EXPERIMENTAL
Intervention: Digital imaging method for tooth color measurement
Number of subjects: 14
Study: 15510758

Group type: EXPERIMENTAL
Intervention: Daily supplementation of ferrous sulfate (200 mg) for 2 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Weekly supplementation of ferrous sulfate (200 mg) for 2 months
Number of subjects: 60
Study: 11843823

Group type: EXPERIMENTAL
Intervention: VAD + cyclosporin A
Number of subjects: 75

Group type: COMPARATOR
Intervention: VAD
Number of subjects: 75
Study: 9559811

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 9
Study: 7884022

Group type: EXPERIMENTAL
Intervention: Toloxatone (N = 10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (N = 8)
Number of subjects: 18
Study: 2886110

Group type: EXPERIMENTAL
Intervention: Methylphenidate infusion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 34
Study: 29806872

Group type: EXPERIMENTAL
Intervention: XR-NTX (380 mg intramuscular injections every fourth week)
Number of subjects: 117
Study: 28801415

Group type: EXPERIMENTAL
Intervention: Low-frequency electrical muscle stimulation (LF‐EMS) at 4 Hz, continuous, 5×60 mins per week for 8 weeks (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham placebo (skin level stimulation only, n=30)
Number of subjects: 60
Study: 26147977

Group type: EXPERIMENTAL
Intervention: Clinical simulation intervention group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Traditional lecture control group
Number of subjects: 98
Study: 24247300

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 μg/kg/min)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Low-dose nesiritide (0.005 μg/kg/min without bolus)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 21173349

Group type: EXPERIMENTAL
Intervention: Ross procedure
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Mechanical valve replacement with optimal self-management anticoagulation therapy
Number of subjects: 1324
Study: 18158199

Group type: EXPERIMENTAL
Intervention: Betamethasone oral mini-pulse (OMP) therapy (5 mg orally on 2 consecutive days per week for 3 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Topical triamcinolone acetonide (0.1%) paste (applied thrice daily for 3 months)
Number of subjects: 49
Study: 16751936

Group type: EXPERIMENTAL
Intervention: Transeptal approach (TSA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retrograde arterial approach (RAA)
Number of subjects: 100
Study: 14598949

Group type: EXPERIMENTAL
Intervention: Dialysis machines disinfected after each session (n = 2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dialysis machines disinfected at the end of the day (n = 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: General hygiene precautions reinforcement
Number of subjects: 15
Study: 10972608

Group type: EXPERIMENTAL
Intervention: 4% sevoflurane/nitrous oxide 67%/oxygen 33% (sevoflurane group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: etomidate, 0.2 mg/kg (intravenous group)
Number of subjects: 20
Study: 8725722

Group type: EXPERIMENTAL
Intervention: Plasma tissue factor (TF) concentration
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Factor VII activity (FVIIc)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Factor VII antigen (FVIIag)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Correlation between TF and FVII
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: FVII activity and concentration correlation
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: FVII activity with age
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: FVII concentration and age correlation
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: FVII ratio between FVIIc and FVIIag
Number of subjects: 498